MS

Goldman Sachs shares rose 38.6% over the past year. Analysts are evaluating whether strong M&A activity, AI projects, cost cuts, and shareholder returns will keep the momentum going.

A Morgan Stanley price target raise just reignited the AI cloud infrastructure trade, sending Oracle surging on a day when the broader market slipped into the red. Whether the rally reflects genuine conviction or a short-term narrative reset is the question investors need to answer before sizing up.

ZUG, Switzerland and BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 1:05 p.m. EST.

Morgan Stanley downgraded Peloton to Underweight from Equal Weight. The downgrade reflects concerns that consumers are shifting toward strength training and gym workouts, which could pressure Peloton's subscriber growth.

Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that Gilad Mamlok, Senior Vice President and Chief Financial Officer, is scheduled to participate in the following two upcoming…

Bank of America’s capital return strategy is supported by solid earnings momentum, a strong capital cushion, and ample buyback capacity. These factors are said to underpin the bank’s shareholder‑return plans.

Morgan Stanley (MS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Morgan Stanley is positioned as the leading contender for the "lead left" role in Anthropic’s $2 trillion IPO. Goldman Sachs is expected to act as a stabilisation agent in the deal.